Stockreport
MHRA grants UK patients early access to Akcea Therapeutics' Volanesorsen for FCS [Seeking Alpha]
Last akcea therapeutics earnings: 8/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.akceatx.com/media-investors/press-releases
PDF
MHRA grants UK patients early access to Akcea Therapeutics' Volanesorsen for FCSAkcea Therapeutics (NASDAQ:AKCA)announces that volanesorsen has been granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) by the UK'sMedicines and Healthcare Products Regulatory Agency (MHRA), for the treatment of familial chylomicronaemia syndrome (FCS), a rare genetic lipid disorder.This decision will enable patients to access volanesorsen before the European Commission makes a formal decision for its use in Europe.FCS is a severe, rare disorder characterised by extremely high levels of triglycerides, daily symptoms such as abdominal pain, and the risk of recurrent, potentially fatal, acute pancreatitis.Click to subscribe to real-time analytics on AKCANow read:Meridian Bio restructures into two business units »
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AKCA | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AKCA alerts
AKCA alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKCA alerts
High impacting AKCEA THERAPEUTICS news events
Weekly update
A roundup of the hottest topics
AKCA
NEWS
NEWS
- Akcea Therapeutics files for mixed shelf offering [Seeking Alpha][Seeking Alpha]
- Akcea Therapeutics files for mixed shelf offering [Seeking Alpha][Seeking Alpha]
- Akcea Therapeutics Inc (NASDAQ: AKCA) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $45.00 price target on the stock.[MarketBeat]
- Akcea Therapeutics: How To Profit On The Waylivra CRL? [Seeking Alpha][Seeking Alpha]
- Akcea Therapeutics: How To Profit On The Waylivra CRL? [Seeking Alpha][Seeking Alpha]
- More
AKCA
SEC Filings
SEC Filings
- 9/18/18 - Form S-3ASR
- 9/18/18 - Form 8-K
- 9/6/18 - Form 8-K
- AKCA's page on the SEC website
- More